BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders (“Holders”) of its senior secured convertible notes (the “Notes”) have agreed to amend certain terms of the Notes and other concessions,

Patients with moderate to severe plaque psoriasis showed meaningful improvements in skin, itch and quality-of-life measures among PASI 75 non-responders treated with OTEZLA, according to a post hoc sub-analysis of data from the phase 3 ESTEEM 1 trial

Investors and other interested parties are invited to listen to the conference call

He will report to President and Chief Executive Officer Zachary Parker and support each of DLH’s operating units in implementing a long-term technology strategy for the company.

TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present at the 2018 Janney Montgomery Scott Healthcare Conference

The Arizona Bioindustry Association (AZBio) today announced that Calimmune, Inc., acquired by CSL Limited in 2017, will be honored as the Arizona Bioscience Company of the Year by the state’s bioscience and business community at the 2018 AZBio Award on Oct. 3 at the Phoenix Convention Center.

The Maryland Tech Council (MTC) will hold its third annual Bio+Tech18 Conference on September 20, 2018 at the Baltimore Hilton. Bringing together leading companies and organizations from across the Mid-Atlantic region to discuss pressing industry topics, more than 400 life sciences, Health IT and technology professionals are expected to attend.

Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has expanded its OnTrak-A solution into Iowa and Nebraska with one of the nation’s leading health plans, which is the second largest plan in both states.

Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD).

The Hyundai Hope On Wheels Foundation embarks on a nationwide tour this September in honor of National Childhood Cancer Awareness Month to award $14.1 million to 38 researchers, surpassing $145 million in total giving.